These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9087973)

  • 1. Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the "super-off" phenomenon.
    Dziewczapolski G; Menalled LB; Savino MT; Mora M; Stefano FJ; Gershanik O
    Mov Disord; 1997 Mar; 12(2):159-66. PubMed ID: 9087973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
    Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different inhibition of conditioned avoidance response by clozapine and DA D1 and D2 antagonists in male mice.
    Aguilar MA; Marí-Sanmillán MI; Morant-Deusa JJ; Miñarro J
    Behav Neurosci; 2000 Apr; 114(2):389-400. PubMed ID: 10832799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice.
    Xu R; Hranilovic D; Fetsko LA; Bucan M; Wang Y
    Mol Psychiatry; 2002; 7(10):1075-82. PubMed ID: 12476322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D4 receptor-mediated presynaptic inhibition of GABAergic transmission in the rat supraoptic nucleus.
    Azdad K; Piet R; Poulain DA; Oliet SH
    J Neurophysiol; 2003 Aug; 90(2):559-65. PubMed ID: 12711714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol.
    Kuoppamäki M; Seppälä T; Syvälahti E; Hietala J
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1262-7. PubMed ID: 8383744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation by group I mGLU receptor activation and group III mGLU receptor blockade of locomotor responses induced by D1-like and D2-like receptor agonists in the nucleus accumbens.
    Rouillon C; Degoulet M; Chevallier K; Abraini JH; David HN
    Brain Res; 2008 Mar; 1198():44-54. PubMed ID: 18261716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G; Rogóz Z; Wieczorek A
    Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
    Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
    Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tonic modulation of inhibition by dopamine D4 receptors in the rat hippocampus.
    Romo-Parra H; Aceves J; Gutiérrez R
    Hippocampus; 2005; 15(2):254-9. PubMed ID: 15476261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes.
    Singh AN; Barlas C; Singh S; Franks P; Mishra RK
    J Psychiatry Neurosci; 1996 Jan; 21(1):29-35. PubMed ID: 8580115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
    Dhir A; Kulkarni SK
    Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical psychopharmacology: the example of clozapine (Leponex)].
    Péré JJ
    Encephale; 1995 Jun; 21 Spec No 3():9-12. PubMed ID: 7628347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.